• Aldeyra Therapeutics named Darlene Deptula-Hicks to its board as it moves toward potential commercialization of its immune-mediated disease pipeline.
• Deptula-Hicks is acting CFO at Normunity, a clinical-stage cancer biotech.
• She previously served as CFO of F-star Therapeutics.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aldeyra Therapeutics Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260609197950) on June 10, 2026, and is solely responsible for the information contained therein.